Trialbee, a global technology provider for patient matching and engagement in clinical trials, has announced a partnership with Clinerion, a worldwide medical data informatics company with a global research network comprised of 30.2 million patients online across 69 healthcare organizations in 15 countries. This partnership will aim to accelerate time to market by shortening patient recruitment and enrollment timelines and will reduce costs associated with patient recruitment and loss-to-follow-up.
“This partnership significantly broadens our global reach and allows us to expand our data set for predictable intelligence-based patient recruitment and retention to support traditional and decentralized trials,” said Lollo Eriksson, CEO of Trialbee. “This is a great opportunity for both organizations to make trials simpler for investigators and to deliver on our commitment of expediting clinical research by optimizing the use of real-world data.”
More than 80% of trials are delayed and approximately 30% of sites never enroll patients because of limited access to patients who match the study criteria. The Trialbee platform provides full transparency of the status of the referred patient flow throughout the entire clinical trial and continuously offers sites and sponsors full insight into the effectiveness of recruitment strategies.
Read the full release, here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.